TOKYO -- Japan is on the verge of initiating a fast-track approval process for Gilead Sciences' antiviral drug remdesivir to treat patients infected by the novel coronavirus, Prime Minister Shinzo Abe said Monday.
Japan's health ministry will place remdesivir on a shortened authorization track once another nation certifies the drug to treat COVID-19. Results from international clinical trials are expected shortly.
